









SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. <b>09403-0003 DI1</b>	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  <b>Ajay GUPTA</b>	
	FILING DATE <b>HEREWITH</b>	ART UNIT Not yet assigned

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	H	Sunder-Plassmann et al., <u>Nephrol Dial Transplant</u> , 11:1797-1802 (1996).	
	I	Rubinger et al., <u>Amer. J. Kidney Diseases</u> , VII No. 2:125-129 (1986).	
	J	Zanen et al., <u>Nephrol Dial Transplant</u> , 11:820-824 (1996).	
	K	<u>The Merck Index</u> , Merck and Co., Inc., Rahway, NJ, Budavari Ed., 11 <sup>th</sup> Edition:3969 (1989).	
	L	<u>Dorland's Illustrated Medical Dictionary</u> , WB Saunders Co., 27 <sup>th</sup> Edition:462,741,837,1541 (1985).	
	M	Berner et al., <u>J. Nutr.</u> , 115:1042-1049 (1985).	
	N	Hazell et al., <u>Br. J. Nutr.</u> , 39:631-639 (1978).	
	O	Basta, et al., Iron deficiency anemia and the productivity of adult males in Indonesia, <u>Am. J. Clin. Nutr.</u> , 32:916 (1979).	
	P	Brown et al., Intravenously administered saccharated iron oxide in the treatment of hypochromic anemia, <u>JAMA</u> , 144:1084-1089 (1950).	
	Q	Calvar et al., Intravenous administration of iron gluconate during hemodialysis, <u>Iron Research</u> , New York:Plenum Press, 1994:219-228.	
EXAMINER SIGNATURE 	DATE CONSIDERED <b>9/16/05</b>		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. <b>09403-0003 DI1</b>	APPLICATION NUMBER <b>Not yet assigned</b>
	FIRST NAMED INVENTOR  <b>Ajay GUPTA</b>	
	FILING DATE <b>HEREWITH</b>	ART UNIT <b>Not yet assigned</b>

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	R	Cook et al., Iron deficiency: The global perspective, In: Hershko, C. Ed. Progress in Iron Research, New York: Plenum Press, 1994:219-228.	
	S	Drueke et al., Iron deficiency and erythropoietin in renal anaemia: developing the optimum treatment strategy, In: Highlights Report, The Oxford Forum, Worcester, College, Oxford, 1996. CBC Oxford, Magdalen Centre, The Oxford Science Park, Oxford, UK.	
	T	Fishbane et al., The safety of intravenous iron dextran in Hemodialysis Patients, Am. J. Kidney Dis., 28:529-534 (1996).	
	U	Lieberman et al., Association of maternal hematocrit with premature labor, Am. J. Obstet. Gynecol., 159:107 (1988).	
	V	Lozoff et al., Long-term developmental outcome of infants with iron deficiency, N. Engl. J. Med., 325:687 (1991).	
	W	NKF-DOQI clinical practical guidelines for the treatment of anemia of chronic renal failure, Am. J. Kid. Dis., 30:S192-S137 (1997).	
	X	Ohira et al., Work capacity, heart rate and blood lactate responses to iron treatment, Br. J. Haematol., 41:365 (1979).	
	Y	Osiki et al., The effects of therapy on the developmental scores of iron-deficient infants, Pediatrics, 71:877 (1983).	
EXAMINER SIGNATURE			DATE CONSIDERED <b>9/16/05</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. 09403-0003 DI1	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  Ajay GUPTA	
	FILING DATE HEREWITH	ART UNIT Not yet assigned

## NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	Z	Oski et al., Effect of iron therapy on behavior performance in nonanemic, iron-deficient infants, <u>Pediatrics</u> , 71:877 (1983).	
	AA	Schultink et al., Low compliance with an iron-supplementation program: a study among pregnant women in Jakarta, Indonesia, <u>Am.J. Clin. Nutr.</u> , 32:916 (1979).	
	AB	Stockman, The treatment of chlorosis by iron and some other drugs, <u>Br. Med. J.</u> , I:881-885 (1983).	
	AC	Yoshifumi Tsuji et al., Effect of recombinant human erythropoietin or anamia after gastectomy, <u>Eur. J. Surg.</u> , 161:29-33 (1995).	
	AD	Shimamatsu, Experience with i.v. iron chondroitin-sulphate colloid in Japanese haemodialysis patients, <u>Nephrol Dial Transplant</u> , 13:1053 (1998).	
	AE	The National Formulary VII, 165 (1942).	
	AF	Dainippon Pharmaceutical product description for BLUTAL <sup>®</sup> Injection, 175-177 (1994).	
	AG	Erslev, Drug Therapy, <u>N. Engl. J. Med.</u> , 324 (19):1339-1344 (1991).	
EXAMINER SIGNATURE			DATE CONSIDERED 9/16/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			




SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. 09403-0003 DI1	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  Ajay GUPTA	
	FILING DATE HEREWITH	ART UNIT Not yet assigned

## NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
AH		Moore et al., Incidence, causes, and treatment of iron deficiency anemia in hemodialysis patients, <u>J. Renal. Nutrition</u> , 2:105-112 (1992).	
AI		Kleiner et al., The role of iron and other factors in patients unresponsive to erythropoietin therapy, <u>Seminars in Dialysis</u> , 8:(1):29-34 (1995).	
AJ		Konopka et al., Iron transfer from transferrin to ferritin mediated by polyphosphate compounds, <u>Biochem. Biophys. Acta.</u> , 677:417-423 (1981).	
AK		Konopka et al., Iron transfer from transferrin to ferritin mediated by polyphosphate compounds, <u>Biochem. Biophys. Acta.</u> , 96(3):1408-1413 (1980).	
AL		Morgan, Iron exchange between transferrin molecules mediated by phosphate compounds and other cell metabolites, <u>Biochem. Biophys. Acta.</u> , 499(1):169-177 (1977).	
AM		Kolff, First clinical experience with artificial kidney, <u>Ann. Intern. Med.</u> , 62:608 (1965).	
AN		Scribner et al., The treatment of chronic uremia by means of intermittent hemodialysis; a preliminary report, <u>Trans. Amer. Soc. Artif. Int. Organs.</u> , 6:114 (1960).	
AO		Jacobs et al., Isolation and characterization of genomic and cDNA clones of human erythropoietin, <u>Nature</u> , 313:806-810 (1985).	
EXAMINER SIGNATURE		DATE CONSIDERED	9/16/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			




SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. 09403-0003 DI1	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  Ajay GUPTA	
	FILING DATE HEREWITH	ART UNIT Not yet assigned

## NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	AP	Levin, The impact of epoetin alfa: quality of life and hematocrit level, <u>Am. J. Kid. Dis.</u> , XX (Suppl. 1 (July):16-20 (1992).	
	AQ	Eschbach et al., Iron balance in hemodialysis patients, <u>Ann. Intern. Med.</u> , 87:710-713 (1977).	
	AR	Woorwood, Blood Rev., 4:259-269 (1980).	
	AS	Macdougall et al., Detection of functional iron deficiency during erythropoietin treatment: a new approach, <u>Br. Med. J.</u> , 304:225-226 (1992).	
	AT	Van Wyck et al., Iron status in patients receiving erythropoietin for dialysis-associated anemia, <u>Kidney Int.</u> , 35:712-716 (1989).	
	AU	Wingard et al., Efficacy of oral iron therapy inpatients receiving recombinant human erythropoietin, <u>Am. J. Kid. Dis.</u> , 25:433-439 (1995).	
	AV	MacDougall et al., Poor response to the treatment of renal anaemia with erythropoietin corrected iron..., <u>Br. Med. J.</u> , 299:157-158 (1989).	
	AW	Schaeffer and Schaefer, The hypochromic red cell: a new parameter for monitoring or iron supplementation, <u>J. Perinat. Med.</u> , 23:83-88 (1995).	
EXAMINER SIGNATURE 	DATE CONSIDERED	9/16/05	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. <b>09403-0003 DI1</b>	APPLICATION NUMBER <b>Not yet assigned</b>
	FIRST NAMED INVENTOR  <b>Ajay GUPTA</b>	
	FILING DATE <b>HEREWITH</b>	ART UNIT <b>Not yet assigned</b>

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume+issue number(s), Publisher, city and/or country where published	T
	AX	Horl, How to diagnose and correct iron deficiency during r-huEPO therapy-a consensus report, <u>Nephrol. Dial. Transplant.</u> , 11:246-250 (1996).	
	AY	Sepandj et al., Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic..., <u>Nephrol. Dial. Transplant.</u> , 11:319-322 (1996).	
	AZ	Rosenlof et al., Iron availability is transiently improved by intravenous iron medication in patients..., <u>Clin. Nephrol.</u> , 43:249-255 (1995).	
	BA	Fishbane and Lynn, The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy..., <u>Am. J. Kidney Dis.</u> , 25:426-432 (1995).	
	BB	Macdougall et al., A randomized controlled study of iron supplementation in patients treated with erythropoietin, <u>J. Amer. Soc. Nephrol.</u> , 4:428 (abstract) (1993).	
	BC	Sunder-Plassmann and Horl., Importance of iron supply for erythropoietin therapy, <u>Nephrol. Dial. Transplant.</u> , 10:2070-2076 (1995).	
	BD	Schaeffer and Schaeffer, Management of iron substitution therapy during r-HuEPO therapy in chronic renal failure patients, <u>Erythropoiesis</u> , 3:71-75 (1992).	
	BE	Nyvad et al., Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients, <u>Lancet</u> , 344:1305-1306 (1994).	
EXAMINER SIGNATURE			DATE CONSIDERED
			9/16/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. <b>09403-0003 DI1</b>	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  <b>Ajay GUPTA</b>	
	FILING DATE HEREWITH	ART UNIT Not yet assigned

## NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	BD	Hamstra et al., Intravenous iron dextran in clinical medicine, JAMA, 243:1726-1731 (1980).	
	BE	Kumpf and Holland, Parenteral iron dextran therapy, DICP Ann Pharmacother, 24:162-166 (1990).	
	BF	Weinberg, Iron withholding: a defense against infection and neoplasia, Physiol. Rev., 64-65-102 (1984).	
	BG	Heath et al., Quantitative aspects of iron deficiency in hypochromic anemia, J. Clin. Invest., 11:1293 (1932).	
	BH	Best and Taylor, The Physiological Basis of Medical Practice, The Williams & Wilkins Co., Baltimore, MD pp. 94-99 (1943).	
	BI	Nissim, Intravenous administration of iron, Lancet, 2:49-51 (1947).	
	BJ	Goetsch et al., Observations on the effect of massive doses of iron given intravenously to patients with hypochromic anemia (1946).	
	BK	Cox et al., Valency investigations of iron dextran ('Imferon'), Nature, 207:1202-1203 (1965).	
	BL	Goldberg, In Iron in Clinical Medicine, eds. Wallerstein, Ro Mettler, SR. Berkeley: Univ. of California Press, Vol. 78 (1958).	
EXAMINER SIGNATURE		DATE CONSIDERED	9/16/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. <b>09403-0003 DI1</b>	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  <b>Ajay GUPTA</b>	
	FILING DATE HEREWITH	ART UNIT Not yet assigned




### NON PATENT LITERATURE DOCUMENTS


EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	BM	Hatton et al., Removal of iron dextran by hemodialysis: as in vitro study, Am. J. Kid. Dis., 26(2):327-330 (1995).	
	BN	Pascual et al., Intravenous Fe-Gluconate-Na for iron-deficient patients on hemodialysis, Nephron, 60:121 (1992).	
	BO	Allegra et al., Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria..., Nephron, 57:175-182 (1991).	
	BP	Pollack and Weaver, Guinea pig and human red cell hemolysates release iron from transferrin, J. Lab. Clin. Med., 105(5):629-634 (1985).	
	BQ	Pollack et al., Iron removal from transferrin. An experimental study., Biochim. Biophys. Acta., 497(2):481-487 (1977).	
	BR	Morgan, Studies on the mechanism of iron release from transferrin, Biochim. Biophys. Acta., 580(2):312-326 (1979).	
	BS	Carver and Frieden, Factors affecting the adenosine triphosphate induced release of iron from transferrin, Biochemistry, 17(1):167-172 (1978).	
EXAMINER SIGNATURE			DATE CONSIDERED
			9/16/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. <b>09403-0003 DI1</b>	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  <b>Ajay GUPTA</b>	
	FILING DATE HEREWITH	ART UNIT Not yet assigned

## NON PATENT LITERATURE DOCUMENTS









EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	BT	Nilsen and Romslo, Phrophosphate as a ligand for delivery of iron to isolated rat-liver mitochondria, <u>Biochim. Biophys. Acta.</u> , 766(1):233-239 (1984).	
	BU	Javiad et al., Interactions between infections, malnutrition and iron nutritional status in Pakistani infants..., <u>Acta. Paeditrica Scandinavica - Supplement</u> , 374:141-50 (1991).	
	BV	Byrd and Horwitz, Lactoferrin inhibits or promotes Legionella pneumopilla intracellular multiplication..., <u>J. Clin. Invest.</u> , 88(4):1103-1112 (1991).	
	BW	Ristroph et al., Chemically defined medium for Legionella pneumophila growth, <u>J. Clin. Microbiology</u> , 13(1):115-119 (1981).	
	BX	Feeley et al., Primary isolation media for Legionnaires disease bacterium, <u>Journal of Clinical Microbiology</u> , 8(3):320-5 (1978).	
	BY	Maurer et al., Paramagnetic pyrophosphate. Preliminary studies on magnetic resonance contrast enhancement of acute myocardial..., <u>Investigative Radiology</u> , 25(2):153-63 (1990).	
	BZ	Stevenson et al., The toxicity of Sn-pyrophosphate: clinical manifestations prior to acute LD50, <u>J. Nucl. Med.</u> , 15:252-256 (1974).	

EXAMINER SIGNATURE		DATE CONSIDERED	9/16/05
--------------------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. 09403-0003 DI1	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  Ajay GUPTA	
	FILING DATE HEREWITH	ART UNIT Not yet assigned

## NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	CA	Harken et al., Early ischemia after complete coronary ligation in the rabbit, dog, pig and monkey, Am. J. Physiol., 241:H202 (1981).	
	CB	Sillen and Martell, Stability constants of metal-ion complexes, The Chemical Society, London, (select pages only) (1964).	
	CD	Kornberg, On the metabolic significance of phosphorolytic and pyrophosphorolytic reactions, In Kasha M, Pullman B, eds. <u>Horizons on Biochemistry</u> , New York, Academic Press, pp. 251-264 (1962).	
	CE	Jung et al., The fate of intravenously injected 32-p-pyrophosphate in dogs, Amer. J. Physiol., 218:1757 (1970).	
	CF	Fleisch and Bisaz, Mechanism of calcification: inhibitory role of pyrophosphate, Nature (Lond.), 195:911 (1962).	
	CG	Fleisch, in Fleisch H, ed., <u>Bisphosphonates in bone disease: from the laboratory to the patient</u> , 2 <sup>nd</sup> ed. Carnforth, Lancs, England: The Parthenon Publishing Group Ltd., pp. 31-33 (1995).	
	CH	U.S. Renal Data System, USRDS 1995 Annual Data Report., The National Institutes of Health, National Institute of Diabetes and digestive and Kidney Diseases, Bethesda, MD (1995).	
EXAMINER SIGNATURE		DATE CONSIDERED	9/16/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 808; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. <b>09403-0003 DI1</b>	APPLICATION NUMBER Not yet assigned
	FIRST NAMED INVENTOR  <b>Ajay GUPTA</b>	
	FILING DATE <b>HEREWITH</b>	ART UNIT Not yet assigned

**NON PATENT LITERATURE DOCUMENTS**

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
	CI	Ifudo et al., The intensity of hemodialysis and the response to rerythropoietin in patients with end stage renal disease, <u>N. Engl. J. Med.</u> , 334:420-425 (1996).	
	CJ	Cheuk et al., Kinetics of pyrophosphate induced iron release from fiferic ovotranferrin, <u>J. of Inorganic Biochemistry</u> , 29:301-311 (1987).	
	CK	Fishbane et al., Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation, <u>Am. J. Kidney Diseases</u> , 26:41-46 (1995).	
	CL	Hurrett et al., Iron fortification of infant cerals: a proposal for the use of ferrous fumarate..., <u>Am. J. Clin. Nutr.</u> , 49:1274-82 (1989).	
	CM	Moore, An outline of iron metabolism, pp. 5-7 (only information available).	
	CN	Nilsen, Effects pf calcium on hepatocyte iron uptake from tranferrin iron-pyrophosphate and iron-ascorbate. (only information available; best copy).	
	CO	Schibler, Inhibition by pyrophosphate and poly-phosphate of aortic calcification induced by vitamin D, in rats, <u>J. Clin. Sci.</u> , 35:363-372 (1968).	
	CP	Tsuji et al., <u>Eur. J. Surg.</u> 161:29-33 (1995)	
	CQ	Starkenstein, E., Beitrage zur Pharmakologie des Eisens., Archiv fur experiment, <u>Path. u. Pharmacol.</u> 118:131-191 (1921)	
EXAMINER SIGNATURE			DATE CONSIDERED
			9/16/25

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.